Side-by-side · Research reference

CartalaxvsCJC-1295 (no DAC)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED10/32 cited

BPhase 1HUMAN-REVIEWED15/51 cited

Cartalax

Bioregulator Peptide · Khavinson School

CartilagePrimary tissuePovorozniuk 2007

MSC → ChondrocyteDifferentiation axisLinkova 2023

BMD ↑Bone density effectPovorozniuk 2007

SQ · Protocol Unspecified

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

01Mechanism of Action

Parameter

Cartalax

CJC-1295 (no DAC)

Primary target

Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023

Pituitary GHRH receptorTeichman 2006

Pathway

Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

Downstream effect

Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023 Povorozniuk 2007

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Feedback intact?

—

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Origin

Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

Cartalax

CJC-1295 (no DAC)

Animal model dose

Unspecified (cartilaginous tissue extract protocol)

Rat study; extract preparation details not indexed in available abstracts.

—

Human dosing

Not established in PubMed-indexed literature

Russian-tradition protocols exist but lack peer-reviewed Western validation.

—

Evidence basis

Animal mechanistic studies only

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Standard dose

—

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

Frequency

—

1–2× daily (pre-sleep ± morning)

Lower / starter dose

—

50 mcg per dose

Duration

—

8–12 weeks on / 4 off (anecdotal)

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

03Metabolic / Fat Loss Evidence

Parameter

Cartalax

CJC-1295 (no DAC)

Fat loss evidence

None — primary target is cartilage and bone tissue, not adipose

—

04Side Effects & Safety

Parameter

Cartalax

CJC-1295 (no DAC)

Documented adverse effects

None reported in indexed animal studies

—

Human safety data

Not available in PubMed-indexed literature

—

Injection site reaction

—

Erythema, mild pruritus

Flushing / headache

—

Common transient effect

Cortisol elevation

—

Minimal at standard doses

Prolactin elevation

—

Minimal

Glucose intolerance

—

Possible at high cumulative doses

IGF-1 elevation

—

Dose-dependent; monitor with chronic use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

Cartalax

·Unknown due to lack of human clinical trial data

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Cartalax

·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

Cartalax

CJC-1295 (no DAC)

1. Route

Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

2. Frequency

Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.

Subcutaneous, abdomen or thigh. Rotate sites.

3. Storage

Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

4. Storage

—

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Cartalax

— no documented stacks

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998